Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT
In summary, refined RT/RCT strategies with PET-CT and IMRT/VMAT enable the intensification of multimodal treatment. Reduction of toxicities with IMRT/VMAT widens the therapeutic window. The coincidence of intensified treatment, improved outcomes, and higher toxicity rates in PET-CT-staged patients emphasizes the need for a detailed risk-benefit assessment during planning and application of treatment modalities.
Authors
- Rami A. El Shafie (ORCID: https://orcid.org/0000-0002-1355-7882)
- Mahalia Zoe Anczykowski
- Manuel Guhlich (ORCID: https://orcid.org/0000-0002-2599-6196)
- Tobias Raphael Overbeck (ORCID: https://orcid.org/0000-0002-2579-0171)
- Markus Schirmer (ORCID: https://orcid.org/0000-0003-1375-4496)
- Julian Muster
- Niklas Josua Alt
- Marcus Edelmann
- Carla Marie Zwerenz
- Martin Leu (ORCID: https://orcid.org/0000-0002-3883-6837)
- Leif H. Dröge (ORCID: https://orcid.org/0000-0002-5378-4246)
- Stefan Rieken (ORCID: https://orcid.org/0009-0000-7018-2856)
- Friederike Braulke
Institutions
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- Strahlentherapie und Onkologie
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1007/s00066-025-02377-0
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00